血浆纤维蛋白原在宫颈癌预后评估中的应用
详细信息    查看全文 | 推荐本文 |
  • 英文篇名:Pretreatment of Plasma Fibrinogen Level as a Potential Prognostic Factor for Cervical Cancer
  • 作者:沈秀华 ; 司国淼 ; 谢娅
  • 英文作者:SHEN Xiuhua;SI Guomiao;XIE Ya;Department of Obstetrics and Gynecology, Linying County People's Hospital;Department of Obstetrics and Gynecology, First Hospital of Zhengzhou University;
  • 关键词:宫颈癌 ; 血浆纤维蛋白原 ; 总体生存时间 ; 预后
  • 英文关键词:cervical cancer;;plasma fibrinogen;;overall survival;;prognosis
  • 中文刊名:HNZG
  • 英文刊名:Journal of Henan Medical College
  • 机构:临颍县人民医院妇产科;郑州大学第一附属医院妇产科;
  • 出版日期:2019-04-15
  • 出版单位:河南医学高等专科学校学报
  • 年:2019
  • 期:v.31;No.147
  • 基金:国家自然科学基金(81202070)
  • 语种:中文;
  • 页:HNZG201902001
  • 页数:5
  • CN:02
  • ISSN:41-1436/R
  • 分类号:5-9
摘要
目的探讨术前血液中血浆纤维蛋白原(plasma fibrinogen,FIB)在宫颈癌患者中的表达水平及其预后的关系。方法检测126例宫颈癌患者的FIB水平,回顾性分析该指标对患者临床病理特点及预后的影响。结果FIB与宫颈癌患者的国际妇产科联盟(international federation of gynecology and obstetrics, FIGO)临床分期、病理分级、淋巴结转移和复发状态相关(P<0.05)。单因素分析结果显示FIB水平(P<0.001)、FIGO临床分期(P<0.01)、病理分级(P<0.05)、淋巴结转移(P<0.05)和肿瘤复发(P<0.01)是影响宫颈癌患者总体生存时间(overall survival, OS)的不良危险因素;多因素分析结果显示,FIB水平与宫颈癌患者OS之间,差异有统计学意义(P<0.05)。结论术前FIB高水平预示宫颈癌患者预后较差,FIB可能为宫颈癌患者预后的独立危险因素。
        Objective To explore the relationship of peripheral blood plasma fibrinogen(FIB) with prognosis in cervical cancer patients.Methods FIB levels were calculated before therapies to analyze their influence on clinical pathology of 126 patients with cervical cancer.Results The results revealed that high FIB levels were more common in patients with high clinical FIGO stage, pathological grade, LNM, recurrent state(P<0.05). In addition, univariate analysis revealed that patients with FIB(P<0.001), FIGO stage(P<0.01), pathological grade(P<0.05), lymph node metastasis(P<0.05), and recurrent state(P<0.01) showed significantly decreased OS. Importantly, multivariate analysis confirmed independent significant correlations between high FIB and OS in cervical cancer patients(P<0.05).Conclusion Preoperative FIB predict poor prognosis in ovarian cancer, and FIB may be an independent risk factor in patients with cervical cancer.
引文
[1] 周晖,刘昀昀,林仲秋.《2017 NCCN宫颈癌临床实践指南》解读[J].中国实用妇科与产科杂志,2017,33(1):100-107.
    [2] MEIJER C,STEENBERGEN R D M.Gynaecological cancer:novel molecular subtypes of cervical cancer potential clinical consequences[J].Nat Rev Clin Oncol,2017,14(7):397-398.
    [3] KOESTLER D C,USSET J,CHRISTENSEN B C,et al.DNA methylation-derived neutrophil-to-lymphocyte ratio:an epigenetic tool to explore cancer inflammation and outcomes[J].Cancer Epidemiol Biomarkers Prev,2017,26(3):328-338.
    [4] RASMUSSEN L J H,SCHULTZ M,GAARDSTING A,et al.Inflammatory biomarkers and cancer:CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer[J].Int J Cancer,2017,141(1):191-199.
    [5] WANG H,ZHAO J,ZHANG M,et al.The combination of plasma fibrinogen and neutrophil lymphocyte ratio (F-NLR) is a predictive factor in patients with resectable non small cell lung cancer[J].J Cell Physiol,2018,233(5):4216-4224.
    [6] FAN S,GUAN Y,ZHAO G,et al.Association between plasma fibrinogen and survival in patients with small-cell lung carcinoma[J].Thorac Cancer,2018,9(1):146-151.
    [7] ZHANG X,LONG Q.Elevated serum plasma fibrinogen is associated with advanced tumor stage and poor survival in hepatocellular carcinoma patients[J].Medicine (Baltimore),2017,96(17):e6694.
    [8] OBATA J,TANAKA N,MIZUNO R,et al.Plasma fibrinogen level:an independent prognostic factor for disease-free survival and cancer-specific survival in patients with localised renal cell carcinoma[J].BJU Int,2016,118(4):598-603.
    [9] 周琦,吴小华,刘继红,等.宫颈癌诊断与治疗指南(第四版)[J].中国实用妇科与产科杂志,2018,34(6):613-622.
    [10] 张晓磊,彭娟,郑建华.宫颈癌FIGO分期的修订及治疗[J].国际生殖健康/计划生育杂志,2011,30(2):153-154.
    [11] TIAN Y,HONG M,JING S,et al.Clinical and prognostic effect of plasma fibrinogen in renal cell carcinoma:a meta-analysis[J].Biomed Res Int,2017,2017:1-8.
    [12] PERISANIDIS C,PSYRRI A,COHEN E E,et al.Prognostic role of pretreatment plasma fibrinogen in patients with solid tumors:a systematic review and meta-analysis[J].Cancer Treat Rev,2015,41(10):960-970.
    [13] SIMMONDS M J,Meiselman H J,Baskurt O K.Blood rheology and aging[J].J Geriatr Cardiol,2013,10(3):291-301.
    [14] MOSESSON M W.Fibrinogen and fibrin structure and functions[J].J Thromb Haemost,2005,3(8):1894-1904.
    [15] LIP G Y,CHIN B S,BLANN A D.Cancer and the prothrombo-tic state[J].Lancet Oncol,2002,3(1):27-34.
    [16] SEEBACHER V,POLTERRAUER S,GRIMM C,et al.The prognostic value of plasma fibrinogen levels in patients with endometrial cancer:a multi-centre trial[J].Br J Cancer,2010,102(6):952-956.
    [17] AMRAIN D L.Regulation of fibrinogen biosynthesis:glucocorticoid and interleukin-6 control[J].Blood Coagul Fibrinolysis,1990,1(4/5):443-446.
    [18] SIMPSON-HAIDARIS P J,RYBARCZYK B.Tumors and fibrinogen.The role of fibrinogen as an extracellular matrix protein[J].Ann N Y Acad Sci,2001,936(1):406-425.
    [19] SAHNI A,SIMPSON-HAIDARIS P J,SAHNI S K,et al.Fibrinogen synthesized by cancer cells augments the proliferative effect of fibroblast growth factor-2 (FGF-2)[J].J Thromb Haemost,2008,6(1):176-183.
    [20] WITSCH E,SELA M,YARDEN Y.Roles for growth factors in cancer progression[J].Physiology (Bethesda),2010,25(2):85-101.
    [21] ZHENG S,SHEN J,JIAO Y,et al.Platelets and fibrinogen facilitate each other in protecting tumor cells from natural killer cytotoxicity[J].Cancer Sci,2009,100(5):859-865.
    [22] ZHANG F,WANGY,SUN P,et al.Fibrinogen promotes malignant biological tumor behavior involving epithelial-mesenchymal transition via the p-AKT/p-mTOR pathway in esophageal squamous cell carcinoma[J].J Cancer Res Clin Oncol,2017,143(12):2413-2424.
    [23] YH X,BRABLETZ T,KANG Y,et al.Upholding a role for EMT in breast cancer metastasis[J].Nature,2017,547(7661):E1-E3.
    [24] POLTERAUER S,GRIMM C,ZEILLINGER R,et al.Association of C-reactive protein (CRP) gene polymorphisms,serum CRP levels and cervical cancer prognosis[J].Anticancer Res,2011,31(6):2259-2264.
    [25] NAKAMURA K,NAKAYAMA K,ISHIKAWA M,et al.High pre-treatment plasma D-Dimer level as a potential prognostic biomarker for cervical carcinoma[J].Anticancer Res,2016,36(6):2933-2938.

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址:北京市海淀区学院路29号 邮编:100083

电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700